The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients—towards a tumor volume-based risk stratification

期刊论文
发表日期：

2024年9月23日

查看全文

Marinus J. Hagens,
Wietske I. Luining,
Liselotte M. S. Boevé,
Remco J. J. Knol,
Ton A. Roeleveld,
Sandra Srbljin,
Saskia Weltings,
Jose C. C. Koppes,
Daniela E. Oprea-Lager,
André N. Vis,
Pim J. van Leeuwen,
Henk G. van der Poel

摘要

Background/objectives

This study reassesses the diagnostic value of PSMA PET/CT in unfavorable intermediate-risk prostate cancer (PCa) and validates the Prostate Cancer Network the Netherlands (PCNN) subclassification.

Subjects/methods

Men subjected to PSMA PET/CT were analyzed, evaluating the incidence of metastatic disease and its correlation with PCNN subgroups.

Results

Metastatic disease was identified in 12.4% of patients. Higher PCNN subgroups correlated with increased metastatic potential; odds were significantly lower in low metastatic potential cases (OR: 0.19, 95% CI 0.06–0.62; p = 0.01).

Conclusions

Our findings reaffirm PSMA PET/CT’s diagnostic value in unfavorable intermediate-risk PCa and validate the PCNN subclassification, reducing scan burden by 48.1%.